Company Overview of Ontogen Corporation
Ontogen Corporation, a drug discovery and development company, focuses on the advancement of small molecule therapeutic agents for the treatment of cancer, infectious diseases, and chronic medical conditions. It engages in the development of ONT-093, a drug for the prevention and reversal of multi-drug resistance associated with cancer chemotherapy, as well as for the oral bioavailability enhancement of chemotherapeutics Taxol and Taxotere. The company also conducts pre-clinical programs that address solid tumor cancer targets, infectious diseases, type-2 diabetes, and wound healing. Ontogen Corporation was founded in 1992 and is headquartered in Carlsbad, California.
2325 Camino Vida Roble
Carlsbad, CA 92009
Founded in 1992
Key Executives for Ontogen Corporation
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Ontogen Corporation, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.